Crowdonomics
All companies
NowRx logo

NowRx

Operating

NowRx, Inc.

Founded 2015

Visit website

Technology-driven, on-demand pharmacy providing free, same-day delivery

Post-money valuation ⓘ
$303.4M
As of May 2022 · from NowRx Preferred Equity 1 · pre-money + amount raised, not a traded price
Total raised
$48,580,502
Across 5 rounds since 2017
Latest share price
$10.85
NowRx Preferred Equity 1 offering price

Financials

FY2015–FY2020 (no data for FY2019) · from SEC filings · hover any figure for its source
$0
−$247K
2015
$669K
−$663K
2016
$2.5M
−$1.1M
2017
$4.7M
−$3.0M
2018
2019no data
$13.4M
−$10.4M
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2015
FY2016
FY2017
FY2018
FY2020
Income statement
Revenue
$0
$668,695
$2,497,667
$4,743,075
$13,414,400
Cost of goods sold
$0
$573,791
$2,162,965
-$4,108,233
$11,932,203
Gross margin
—
14%
13%
13%
11%
Net income
-$247,240
-$662,535
-$1,092,881
-$3,000,901
-$10,423,845
Taxes paid
$0
$0
$0
—
—
Balance sheet
Cash
$160,765
$175,519
$52,212
$4,253,065
$8,873,706
Accounts receivable
$12,826
$128,552
$269,788
$356,316
$1,156,705
Total assets
$308,161
$459,485
$752,343
$5,681,761
$13,554,205
Short-term debt
$109,551
$210,910
$307,102
—
—
Long-term debt
$445,000
$1,117,500
$2,374,463
$0
$1,939,638
Total liabilities
$554,551
$2,188,261
$2,681,565
$589,495
$4,507,303
Other
Headcount
—
12
16
23
82

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$6.0M
Valuation cap
$25.3M
post-money
$85.0M
post-money
$303.4M
post-money
Reg CF Offering (2017)
NowRX Stock 2
Reg A Offering (2019)
NowRx Preferred Equity 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

NowRx Preferred Equity 1ClosedReg A+ · Preferred Equity · via SeedInvest
Raised $28.4M / $75MPost-money $303.4M
Reg A Offering (2019)ClosedReg A+ · Equity · via SeedInvest
Raised $20M / $20MInvestors 8,918Post-money $85M
Reg A Offering (2018)ClosedReg A+ · Equity · via SI Securities, LLC
Raised $0 / $7M
NowRX Stock 2ClosedReg CF · Preferred Equity · via SeedInvest
Raised —Post-money $25.3M
Reg CF Offering (2017)ClosedReg CF · Debt · via SeedInvest
Raised $200K / $1MValuation cap $6M

Team

4 people
Cary Breese
CEO
Sumeet Sheokand
Chief Technology Officer
Melissa Bostock
Pharmacist-in-Charge
Barry Karlin
Director

Names and titles as disclosed on SEC Form 1-A, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 9 annual reports (FY2017–FY2025)

8,918 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 35 filings on EDGAR
  • Form 1-ZNov 14, 20220001104659-22-117331
    EDGAR
  • Form 1-SASep 28, 20220001104659-22-103473
    EDGAR
  • Form 1-KMay 2, 20220001104659-22-054011
    EDGAR
  • Form 253G2Apr 14, 20220001104659-22-046089
    EDGAR
  • Form 253G2Jan 21, 20220001104659-22-006426
    EDGAR
  • Form 1-UOct 12, 20210001104659-21-124903
    EDGAR
  • Form 253G2Sep 30, 20210001104659-21-120970
    EDGAR
  • Form 1-SASep 28, 20210001104659-21-119941
    EDGAR
Source: ManualCIK 0001702206Share price $10.85

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.